Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

A2487

Sigma-Aldrich

Cotrimoxazole, Ready Made Solution

100 mg/mL in DMSO

Sinónimos:

Trimethoprim-Sulfamethoxazole, TMP-SMX

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C14H18N4O3 · 5 C10H11N3O3S
Número de CAS:
8064-90-2
Peso molecular:
1556.71
UNSPSC Code:
51102829
NACRES:
NA.85

form

liquid

Quality Level

200

concentration

100 mg/mL in DMSO

color

colorless to faint yellow

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
fungi
parasites

mode of action

DNA synthesis | interferes

shipped in

dry ice

storage temp.

−20°C

InChI

1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)

InChI key

WZRJTRPJURQBRM-UHFFFAOYSA-N

Application

Cotrimoxazole has been used as an antimicrobial agent.

Biochem/physiol Actions

Cotrimoxazole, a combination of trimethoprim and sulfamethoxazole, interferes with the cellular metabolism of folic acid in the bacterial cell by blocking the biosynthesis of nucleotides. Trimethoprim binds to dihydrofolate reductase (DHFR) which inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), resulting in an antimicrobial effect. Sulfamethoxazole interferes with the synthesis of nucleic acids in sensitive microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid. The net effect of these actions is to inhibit thymidine synthesis which prevents bacterial DNA synthesis.

Packaging

1ml

Preparation Note

prepared using a 1:5 mixture of trimethoprim:sulfamethoxazole

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

pictograms

Health hazard
GHS08

signalword

Warning

Hazard Classifications

Aquatic Chronic 3 - Repr. 2

Storage Class

12 - Non Combustible Liquids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nada A Elnadi et al.
Journal of the Egyptian Society of Parasitology, 43(2), 457-462 (2013-11-23)
Pneumocystitis may cause fatal pneumonia in premature, seriously ill infants at intensive care units. The present study evaluated the routine treatment applied at Sohag pediatrics department for neonatal and infantile pneumonia (in NICU & PICU) on PCP and to compare
Oana Maria Parasca et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 117(2), 558-564 (2013-12-18)
Sulfonamides and their different derivatives are extensively used in therapy due to their pharmacological properties. Sulfa drugs were amongst the oldest synthesized antimicrobial agents and are still widely used today to treat different microbial infections. Clinical treatment with sulfonamides has
Désirée Caselli et al.
The Journal of pediatrics, 164(2), 389-392 (2013-11-21)
To determine whether a simplified, 1-day/week regimen of trimethoprim/sulfamethoxazole is sufficient to prevent Pneumocystis (jirovecii [carinii]) pneumonia (PCP). Current recommended regimens for prophylaxis against PCP range from daily administration to 3 consecutive days per week dosing. A prospective survey of
Milind M Baldi et al.
Journal of bronchology & interventional pulmonology, 20(4), 333-337 (2013-10-29)
Pulmonary alveolar proteinosis (PAP) is a rare disease with worldwide distribution and an estimated incidence of 0.36 cases per million. We report a case of a PAP coexisting with Pneumocystis jiroveci pneumonia and Mycobacterium tuberculosis infection. The patient was treated
Heather M Kling et al.
Journal of acquired immune deficiency syndromes (1999), 65(4), 381-389 (2013-10-15)
Despite antiretroviral therapy and trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, Pneumocystis pneumonia remains an important serious opportunistic infection in HIV-infected persons. Pneumocystis (Pc) colonization in HIV-infected individuals and in HIV-uninfected smokers is associated with chronic obstructive pulmonary disease (COPD). We previously developed a
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico